Bloomberg ticker: 6446TT
Market capitalization: $6,191 million
Background: PharmaEssentia Corporation develops and distributes drugs for the treatment of hepatitis, chronic myelogenous leukemia, essential thrombocythemia, myeloid fibrosis, polycythemia vera, hepatitis and cancer. The company was founded in 2003 by a group of Taiwanese-American executives and scientists from American biotech and pharmaceutical companies.
- Rank 1 for profitable growth was the same compared to rank 1 from the previous period
- This is world-class performance compared to 310 mid-sized healthcare companies worldwide
- The profitability rank 1 was the same as the growth rank 1
- The profitability rank of 1 was higher compared to the third rank of the previous period
- This is world-class performance compared to comparable companies
- Growth position 1 was the same compared to the 1st position of the previous period
- This is world-class performance compared to comparable companies
INDEMNIFICATION: This content is for informational purposes only. It is not intended as investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may contain errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.
#Worldclass #benchmarking #PharmaEssentia #Corporation